Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year. The growth was primarily driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. TONMYA recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%.
The company's commercial progress is underscored by TONMYA's coverage, which currently represents approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027. This broad market access is crucial for the drug's adoption and revenue growth, positioning Tonix to capitalize on a condition that has seen limited treatment innovation in over a decade.
Beyond commercial achievements, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, a condition with significant unmet medical needs. Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These pipeline developments highlight Tonix's commitment to addressing CNS and immunology indications with high unmet need.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides the company with the stability to execute its commercial and clinical strategies without immediate capital constraints.
The importance of this announcement lies in Tonix's demonstrated ability to generate substantial revenue from TONMYA, which could signal a turning point for the company as it transitions from a development-stage to a commercial-stage biotech. The strong prescription growth and expanding coverage suggest that TONMYA is gaining traction among physicians and patients, potentially reshaping the fibromyalgia treatment landscape. For investors, the robust revenue and cash position offer a positive outlook, while the pipeline progress underscores the company's long-term growth potential.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new treatment for fibromyalgia in more than 15 years. The company's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is also evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, and advancing a pipeline that includes TNX-2900 for Prader-Willi syndrome, TNX-4800 for Lyme disease prophylaxis, and TNX-1500 for kidney transplant rejection prevention. For more information, visit the company's newsroom at https://nnw.fm/TNXP.
